{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:11:11Z","timestamp":1791396671918,"version":"4.3.3"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40265-023-01881-w","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T22:01:40Z","timestamp":1686780100000},"page":"923-934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes"],"prefix":"10.1007","volume":"83","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"issue":"1","key":"1881_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40263-020-00784-8","volume":"35","author":"A Strzelczyk","year":"2021","unstructured":"Strzelczyk A, Schubert-Bast S. Expanding the treatment landscape for Lennox-Gastaut syndrome: current and future strategies. CNS Drugs. 2021;35(1):61\u201383.","journal-title":"CNS Drugs"},{"issue":"3","key":"1881_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40263-022-00898-1","volume":"36","author":"A Strzelczyk","year":"2022","unstructured":"Strzelczyk A, Schubert-Bast S. A practical guide to the treatment of Dravet Syndrome with anti-seizure medication. CNS Drugs. 2022;36(3):217\u201337.","journal-title":"CNS Drugs"},{"issue":"2","key":"1881_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1055\/s-0040-1701694","volume":"51","author":"D Samanta","year":"2020","unstructured":"Samanta D. Changing landscape of Dravet syndrome management: an overview. Neuropediatrics. 2020;51(2):135\u201345.","journal-title":"Neuropediatrics"},{"key":"1881_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.107966","volume":"168","author":"GJ Sills","year":"2020","unstructured":"Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020;168: 107966.","journal-title":"Neuropharmacology"},{"issue":"2","key":"1881_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/epi4.12580","volume":"7","author":"J Sourbron","year":"2022","unstructured":"Sourbron J, Lagae L. Serotonin receptors in epilepsy: novel treatment targets? Epilepsia Open. 2022;7(2):231\u201346.","journal-title":"Epilepsia Open."},{"issue":"8","key":"1881_CR6","first-page":"1159","volume":"9","author":"D Samanta","year":"2022","unstructured":"Samanta D. Fenfluramine: a review of pharmacology, clinical efficacy, and safety in epilepsy. Children (Basel). 2022;9(8):1159.","journal-title":"Children (Basel)."},{"issue":"16","key":"1881_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22168416","volume":"22","author":"P Martin","year":"2021","unstructured":"Martin P, Reeder T, Sourbron J, et al. An emerging role for sigma-1 receptors in the treatment of developmental and epileptic encephalopathies. Int J Mol Sci. 2021;22(16):1\u201327.","journal-title":"Int J Mol Sci"},{"key":"1881_CR8","unstructured":"Zogenix. Fintepla: summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/. Accessed 28 Apr 2023."},{"key":"1881_CR9","unstructured":"Zogenix. Fintepla (fenfluramine) oral solution, CIV: US prescribing information. 2023. https:\/\/dailymed.nlm.nih.gov\/. Accessed 28 Apr 2023."},{"key":"1881_CR10","unstructured":"Pharmaceuticals and Medical Devices Agency. Fintepla Japanese precscribing information. 2022. https:\/\/www.pmda.go.jp\/. Accessed 28 Apr 2023."},{"issue":"10","key":"1881_CR11","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1080\/03007995.2017.1355781","volume":"33","author":"AS Schoonjans","year":"2017","unstructured":"Schoonjans AS, Marchau F, Paelinck BP, et al. Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population. Curr Med Res Opin. 2017;33(10):1773\u201381.","journal-title":"Curr Med Res Opin"},{"key":"1881_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107866","volume":"226","author":"R Odi","year":"2021","unstructured":"Odi R, Invernizzi RW, Gallily T, et al. Fenfluramine repurposing from weight loss to epilepsy: what we do and do not know. Pharmacol Ther. 2021;226: 107866.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"1881_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/14737175.2021.1877540","volume":"22","author":"AS Schoonjans","year":"2022","unstructured":"Schoonjans AS, Ceulemans B. A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome. Expert Rev Neurother. 2022;22(5):351\u201364.","journal-title":"Expert Rev Neurother"},{"key":"1881_CR14","unstructured":"Reeder T, Martin P, Sourbron J, et al. Dual activity of fenfluramine (Fintepla\u00ae) as a serotonin receptor agonist and positive sigma-1 receptor modulator: implication for disease modification in developmental and epileptic encephalopathies [poster no. 27C]. In: 76th AES Annual Meeting. 2022."},{"key":"1881_CR15","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/0091-3057(88)90089-5","volume":"30","author":"R Fuller","year":"1988","unstructured":"Fuller R, Snoddy H, Robertson D. Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release. Pharmacol Biochem Behav. 1988;30:715\u201321.","journal-title":"Pharmacol Biochem Behav"},{"issue":"34","key":"1881_CR16","doi-asserted-by":"publisher","first-page":"23373","DOI":"10.18632\/oncotarget.25169","volume":"9","author":"M Rodr\u00edguez-Mu\u00f1oz","year":"2018","unstructured":"Rodr\u00edguez-Mu\u00f1oz M, S\u00e1nchez-Bl\u00e1zquez P, Garz\u00f3n J. Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors. Oncotarget. 2018;9(34):23373\u201389.","journal-title":"Oncotarget"},{"issue":"8","key":"1881_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/j.1528-1157.2000.tb00273.x","volume":"41","author":"K Gentsch","year":"2005","unstructured":"Gentsch K, Heinemann U, Schmitz B, et al. Fenfluramine blocks low-Mg2+-induced epileptiform activity in rat entorhinal cortex. Epilepsia. 2005;41(8):925\u20138.","journal-title":"Epilepsia"},{"key":"1881_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fphar.2017.00191","volume":"8","author":"J Sourbron","year":"2017","unstructured":"Sourbron J, Smolders I, de Witte P, et al. Pharmacological analysis of the anti epileptic mechanisms of fenfluramine in scn1a mutant zebrafish. Front Pharmacol. 2017;8:191.","journal-title":"Front Pharmacol"},{"key":"1881_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106777","volume":"177","author":"S Tupal","year":"2021","unstructured":"Tupal S, Faingold CL. Serotonin 5-HT4 receptors play a critical role in the action of fenfluramine to block seizure-induced sudden death in a mouse model of SUDEP. Epilepsy Res. 2021;177: 106777.","journal-title":"Epilepsy Res"},{"issue":"9","key":"1881_CR20","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s11064-021-03358-2","volume":"46","author":"J Li","year":"2021","unstructured":"Li J, Nelis M, Sourbron J, et al. Efficacy of fenfluramine and norfenfluramine enantiomers and various antiepileptic drugs in a zebrafish model of Dravet syndrome. Neurochem Res. 2021;46(9):2249\u201361.","journal-title":"Neurochem Res"},{"issue":"108526","key":"1881_CR21","first-page":"1","volume":"127","author":"P Martin","year":"2022","unstructured":"Martin P, Maurice T, Gammaitoni A, et al. Fenfluramine modulates the anti-amnesic effects induced by sigma-1 receptor agonists and neuro(active)steroids in vivo. Epilepsy Behav. 2022;127(108526):1\u201313.","journal-title":"Epilepsy Behav"},{"issue":"8","key":"1881_CR22","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.clinthera.2018.05.013","volume":"40","author":"A Gammaitoni","year":"2018","unstructured":"Gammaitoni A, Smith S, Boyd B. The lack of effect of food on the pharmacokinetics of ZX008 (Fenfluramine oral solution): results of a single-dose, two-period crossover study. Clin Ther. 2018;40(8):1338\u201346.","journal-title":"Clin Ther"},{"issue":"1","key":"1881_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5414\/CP203276","volume":"57","author":"B Boyd","year":"2019","unstructured":"Boyd B, Smith S, Gammaitoni A, et al. A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects. Int J Clin Pharmacol Ther. 2019;57(1):11\u20139.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"10216","key":"1881_CR24","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","volume":"394","author":"L Lagae","year":"2019","unstructured":"Lagae L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10216):2243\u201354.","journal-title":"Lancet"},{"issue":"3","key":"1881_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","volume":"77","author":"R Nabbout","year":"2020","unstructured":"Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77(3):300\u20138.","journal-title":"JAMA Neurol"},{"key":"1881_CR26","unstructured":"Sullivan J, Lagae L, Cross H, et al. Fenfluramine (Fintepla) in Dravet syndrome: results of a third randomized, placebo-controlled clinical trial (Study 3) [abstract no. 853 plus poster]. In: 76th AES Annual Meeting. 2020."},{"issue":"11","key":"1881_CR27","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1111\/epi.16722","volume":"61","author":"J Sullivan","year":"2020","unstructured":"Sullivan J, Scheffer IE, Lagae L, et al. Fenfluramine HCl (Fintepla\u00ae) provides long-term clinically meaningful reduction in seizure frequency: analysis of an ongoing open-label extension study. Epilepsia. 2020;61(11):2396\u2013404.","journal-title":"Epilepsia"},{"issue":"15 Suppl","key":"1881_CR28","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1212\/WNL.94.15_supplement.4684","volume":"94","author":"J Sullivan","year":"2020","unstructured":"Sullivan J, Auvin S, Pringsheim M, et al. Long-term (2-year) safety and efficacy of adjunctive ZX008 (fenfluramine hydrochloride oral solution) for Dravet syndrome: interim results of an ongoing open-label extension study [abstract]. Neurology. 2020;94(15 Suppl):4684.","journal-title":"Neurology"},{"key":"1881_CR29","unstructured":"Scheffer IE, Devinsky O, Perry MS, et al. Efficacy and tolerability of adjunctive Fintepla (fenfluramine HCl) in an open-label extension study of Dravet syndrome patients treated for up to 3 years [abstract no. 978 plus poster]. In: 74th AES Annual Meeting. 2020."},{"key":"1881_CR30","unstructured":"Sullivan J, Specchio N, Devinsky O, et al. Using a time-to-event analysis to measure treatment effect of fenfluramine (Fintepla\u00ae) on seizure-free days post-hoc analysis of two phase 3 studies in Dravet Syndrome [poster no. 385]. In: 14th EPNS Annual Meeting. 2022."},{"key":"1881_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejpn.2021.01.005","volume":"31","author":"J Sullivan","year":"2021","unstructured":"Sullivan J, Perry MS, Wheless JW, et al. Fenfluramine responder analyses and numbers needed to treat: translating epilepsy trial data into clinical practice. Eur J Paediatr Neurol. 2021;31:10\u20134.","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"1881_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/epi.17106","volume":"63","author":"J Sullivan","year":"2022","unstructured":"Sullivan J, Specchio N, Devinsky O, et al. Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: a time-to-event analysis. Epilepsia. 2022;63(1):130\u20138.","journal-title":"Epilepsia"},{"issue":"Suppl 23","key":"1881_CR33","first-page":"S59","volume":"86","author":"O Devinsky","year":"2019","unstructured":"Devinsky O, Cross JH, Gil-Nagel A, et al. ZX008 (fenfluramine HCl oral solution) significantly reduces frequency of generalized tonic-clonic seizures in Dravet syndrome: pooled analysis from two phase 3 clinical trials [abstract no. 41 plus poster]. Ann Neurol. 2019;86(Suppl 23):S59-60.","journal-title":"Ann Neurol"},{"key":"1881_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108994","volume":"138","author":"KI Bishop","year":"2023","unstructured":"Bishop KI, Isquith PK, Gioia GA, et al. Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: a critical period for early neurodevelopment. Epilepsy Behav. 2023;138: 108994.","journal-title":"Epilepsy Behav"},{"issue":"Suppl 3","key":"1881_CR35","first-page":"282","volume":"62","author":"L Lagae","year":"2021","unstructured":"Lagae L, Auvin S, Knupp K, et al. Impact of fenfluramine on convulsive seizure frequency in young (< 6 years old) patients with dravet syndrome: a long-term open-label study [abstract no. 527]. Epilepsia. 2021;62(Suppl 3):282\u20133.","journal-title":"Epilepsia"},{"issue":"Pt A","key":"1881_CR36","first-page":"1","volume":"121","author":"KI Bishop","year":"2021","unstructured":"Bishop KI, Isquith PK, Gioia GA, et al. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: analysis from a phase 3 long-term extension study in children\/young adults with Dravet syndrome. Epilepsy Behav. 2021;121(Pt A):1\u20139.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"1881_CR37","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/epi4.12624","volume":"7","author":"R Guerrini","year":"2022","unstructured":"Guerrini R, Specchio N, Aledo-Serrano \u00c1, et al. An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: a report from the fenfluramine European Early Access Program. Epilepsia Open. 2022;7(4):578\u201387.","journal-title":"Epilepsia Open."},{"issue":"11","key":"1881_CR38","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1111\/epi.16690","volume":"61","author":"N Specchio","year":"2020","unstructured":"Specchio N, Pietrafusa N, Doccini V, et al. Efficacy and safety of fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a real-world study. Epilepsia. 2020;61(11):2405\u201314.","journal-title":"Epilepsia"},{"issue":"10","key":"1881_CR39","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1111\/epi.17034","volume":"62","author":"A Strzelczyk","year":"2021","unstructured":"Strzelczyk A, Pringsheim M, Mayer T, et al. Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: compassionate use program in Germany. Epilepsia. 2021;62(10):2518\u201327.","journal-title":"Epilepsia"},{"issue":"10","key":"1881_CR40","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1111\/epi.14540","volume":"59","author":"L Lagae","year":"2018","unstructured":"Lagae L, Schoonjans AS, Gammaitoni AR, et al. A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox-Gastaut syndrome. Epilepsia. 2018;59(10):1881\u20138.","journal-title":"Epilepsia"},{"issue":"6","key":"1881_CR41","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamaneurol.2022.0829","volume":"79","author":"KG Knupp","year":"2022","unstructured":"Knupp KG, Scheffer IE, Ceulemans B, et al. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial. JAMA Neurol. 2022;79(6):554\u201364.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1881_CR42","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/epi.17431","volume":"64","author":"KG Knupp","year":"2023","unstructured":"Knupp KG, Scheffer IE, Ceulemans B, et al. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study. Epilepsia. 2023;64(1):139\u201351.","journal-title":"Epilepsia"},{"key":"1881_CR43","doi-asserted-by":"crossref","unstructured":"Bishop K, Isquith P, Gioia G, et al. Fenfluramine treatment improves everyday executive functioning in patients with Lennox-Gastaut syndrome: analysis from a phase 3 clinical trial [presentation]. In: 73rd AAN Annual Meeting. 2021.","DOI":"10.1055\/s-0041-1739606"},{"key":"1881_CR44","doi-asserted-by":"crossref","unstructured":"Bishop K, Isquith P, Gioia G, et al. Fenfluramine (Fintepla\u00ae) treatment improves everyday executive functioning in patients with Lennox-Gastaut syndrome: analysis from a phase 3 clinical trial [abstract no. P12-8.004 plus poster]. Neurology. 2022;98(15 Suppl).","DOI":"10.1055\/s-0041-1739606"},{"key":"1881_CR45","doi-asserted-by":"crossref","unstructured":"Polega S, Bishop K, Isquith P, et al. Fenfluramine treatment is associated with improvement in everyday executive function in adults with Lennox-Gastaut syndrome: post-hoc analysis of dose effects from a phase 3 trial rationale [abstract no. 3.411]. In: 76th AES Annual Meeting. 2022.","DOI":"10.1212\/WNL.0000000000202479"},{"key":"1881_CR46","unstructured":"Scheffer I, Devinsky O, Thiele E, et al. Interim safety analysis of an ongoing open-label extension study of fenfluramine for Dravet syndrome [abstract no. 3.412]. In: 76th AES Annual Meeting. 2022."},{"issue":"108212","key":"1881_CR47","first-page":"1","volume":"122","author":"A Gil-Nagel","year":"2021","unstructured":"Gil-Nagel A, Sullivan J, Ceulemans B, et al. Treatment with fenfluramine in patients with Dravet syndrome has no long-term effects on weight and growth. Epilepsy Behav. 2021;122(108212):1\u20136.","journal-title":"Epilepsy Behav"},{"issue":"11","key":"1881_CR48","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1111\/epi.16638","volume":"61","author":"WW Lai","year":"2020","unstructured":"Lai WW, Galer BS, Wong PC, et al. Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: analysis of an ongoing long-term open-label safety extension study. Epilepsia. 2020;61(11):2386\u201395.","journal-title":"Epilepsia"},{"key":"1881_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejpn.2022.05.006","volume":"39","author":"A Agarwal","year":"2022","unstructured":"Agarwal A, Farfel GM, Gammaitoni AR, et al. Long-term cardiovascular safety of fenfluramine in patients with Dravet syndrome treated for up to 3 years: findings from serial echocardiographic assessments. Eur J Paediatr Neurol. 2022;39:35\u20139.","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"1881_CR50","first-page":"220","volume":"139","author":"CM DeGiorgio","year":"2019","unstructured":"DeGiorgio CM, Curtis A, Hertling D, et al. Sudden unexpected death in epilepsy: risk factors, biomarkers, and prevention. Acta Neurol Scand. 2019;139(3):220\u201330.","journal-title":"Acta Neurol Scand"},{"key":"1881_CR51","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.seizure.2021.10.024","volume":"93","author":"JH Cross","year":"2021","unstructured":"Cross JH, Galer BS, Gil-Nagel A, et al. Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. Seizure. 2021;93:154\u20139.","journal-title":"Seizure."},{"key":"1881_CR52","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s42399-021-00989-y","volume":"3","author":"F Marchese","year":"2021","unstructured":"Marchese F, Cappelletti S, Filippini M, et al. Comorbidities in Dravet syndrome and Lennox-Gastaut syndrome. Comp Clin Med. 2021;3:2167\u201379.","journal-title":"Comp Clin Med."},{"issue":"7","key":"1881_CR53","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1111\/epi.17274","volume":"63","author":"EC Wirrell","year":"2022","unstructured":"Wirrell EC, Hood V, Knupp KG, et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia. 2022;63(7):1761\u201377.","journal-title":"Epilepsia"},{"key":"1881_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.106976","volume":"185","author":"MP Jensen","year":"2022","unstructured":"Jensen MP, Gammaitoni AR, Galer BS, et al. Fenfluramine treatment for Dravet syndrome: real-world benefits on quality of life from the caregiver perspective. Epilepsy Res. 2022;185: 106976.","journal-title":"Epilepsy Res"},{"key":"1881_CR55","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.seizure.2021.06.020","volume":"91","author":"N Devi","year":"2021","unstructured":"Devi N, Madaan P, Asrar MM, et al. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: an indirect treatment comparison. Seizure. 2021;91:316\u201324.","journal-title":"Seizure."},{"issue":"Suppl 3","key":"1881_CR56","first-page":"154","volume":"62","author":"W Linley","year":"2021","unstructured":"Linley W, Hawkins N, Schwenkglenks M, et al. Comparative effectiveness of fenfluramine vs cannabidiol for the treatment of seizures in Dravet syndrome (DS): a network meta-analysis (NMA) [abstract no. 324]. Epilepsia. 2021;62(Suppl 3):154.","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"1881_CR57","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1016\/j.jval.2021.04.817","volume":"24","author":"G Weston","year":"2021","unstructured":"Weston G, Pinsent A, Adams E, et al. A cost-effectiveness analysis of fenfluramine for the treatment of seizures for patients with Dravet syndrome (DS) in the UK setting [abstract no. PND33]. Value Health. 2021;24(Suppl 1):S164\u20135.","journal-title":"Value Health."},{"issue":"1","key":"1881_CR58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40273-022-01209-8","volume":"41","author":"B Wijnen","year":"2023","unstructured":"Wijnen B, Witlox W, Wolff R, et al. Fenfluramine for treating Dravet syndrome: an evidence review group perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2023;41(1):33\u201342.","journal-title":"Pharmacoeconomics"}],"updated-by":[{"DOI":"10.1007\/s40265-023-01919-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01881-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01881-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01881-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T22:19:20Z","timestamp":1702592360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01881-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1881"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01881-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"18 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-023-01919-z","URL":"https:\/\/doi.org\/10.1007\/s40265-023-01919-z","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"James E. Frampton is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}